Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Director comp.
LadRx Corp (CYTR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2018 8-K Quarterly results
Docs: "Substantial Reduction in CytRx Cash Burn Rate This Quarter Company to Host Conference Call Today at 11:00 am ET"
05/08/2018 8-K Quarterly results
Docs: "LOS ANGELES – May 8, 2018"
03/19/2018 8-K Quarterly results
Docs: "CytRx Reports 2017 Financial Results"
11/09/2017 8-K Quarterly results
Docs: "Press Release"
08/03/2017 8-K/A Quarterly results
Docs: "LOS ANGELES – August 3, 2017 –"
08/03/2017 8-K Quarterly results
05/10/2017 8-K Form 8-K - Current report
03/15/2017 8-K/A Form 8-K/A - Current report [Amend]
03/15/2017 8-K Quarterly results
Docs: "LOS ANGELES – March 15, 2017"
11/09/2016 8-K Form 8-K - Current report
07/29/2016 8-K Quarterly results
Docs: "LOS ANGELES – July 29, 2016"
05/11/2016 8-K Quarterly results
Docs: "PRESS RELEASE FOR QUARTER 1, 2016 EARNINGS"
08/06/2013 8-K Quarterly results
Docs: "CytRx Reports 2013 Second Quarter Financial Results Plans to initiate Phase 2b trial in brain cancer in the second half of 2013 and global Phase 3 pivotal trial in soft tissue sarcoma in the first quarter of 2014 LOS ANGELES – CytRx Corporation"
05/09/2013 8-K Quarterly results
Docs: "CytRx Reports 2013 First Quarter Financial Results LOS ANGELES – CytRx Corporation"
03/11/2013 8-K Quarterly results
Docs: "CytRx Reports 2012 Financial Results Data from four oncology clinical trials expected in 2013 Preparations underway for an international Phase 3 pivotal clinical trial with aldoxorubicin in patients with advanced soft tissue sarcomas LOS ANGELES – CytRx Corporation"
11/09/2012 8-K Quarterly results
Docs: "CytRx Reports Third Quarter 2012 Financial Results Reports positive meeting with the FDA to discuss a Phase 3 pivotal trial with aldoxorubicin for patients with advanced soft tissue sarcomas Company is planning to submit a special protocol assessment related to the Phase 3 trial Sufficient capital resources to fund operations through foreseeable future LOS ANGELES – CytRx Corporation"
03/13/2012 8-K Form 8-K - Current report
11/08/2011 8-K Form 8-K - Current report
08/09/2011 8-K Quarterly results
Docs: "CytRx Reports Second Quarter 2011 Financial Results – Data from INNO-206 Phase 1b clinical trial principally in patients with advanced soft tissue sarcomas expected in the fourth quarter 2011 – –Plan to begin INNO-206 Phase 2 clinical trial in soft tissue sarcomas by year end – – Sufficient financial resources to reach key clinical development inflection points in aggressive oncology development programs – LOS ANGELES"
05/05/2011 8-K Form 8-K - Current report
03/11/2011 8-K Form 8-K - Current report
11/08/2010 8-K Quarterly results
Docs: "– Recent highlights include initiation of second Phase 2 clinical trial with bafetinib for advanced prostate cancer and award of non-dilutive funds under the Qualifying Therapeutic Discovery Project – LOS ANGELES CytRx Corporation"
08/09/2010 8-K Form 8-K - Current report
05/06/2010 8-K Quarterly results
Docs: "LOS ANGELES – CytRx Corporation"
03/15/2010 8-K Quarterly results
Docs: "LOS ANGELES CytRx Corporation"
11/09/2009 8-K Quarterly results
Docs: "LOS ANGELES CytRx Corporation"
08/10/2009 8-K Quarterly results
Docs: "CytRx Reports 2009 Second Quarter Financial Results LOS ANGELES CytRx Corporation , a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today reported financial results for the three months ended June 30, 2009. “We have reported considerable progress with our drug development programs, including results from a series of animal trials demonstrating that our oncology drug candidate INNO-206 produced statistically significant shrinkage of ovarian, breast and pancreatic tumors,” said Steven A. Kriegsman, CytRx President and CEO. “With our lead oncology drug candidate tamibarotene, we were notified in June of a positive opinion regarding our application for orphan medicinal product status to the European Medicines Agency as a treatme..."
05/12/2009 8-K Form 8-K -- Current report
03/13/2009 8-K Form 8-K -- Current report
11/12/2008 8-K Quarterly results
Docs: "CytRx Corporation Announces 2008 Third Quarter Financial Results LOS ANGELES – CytRx Corporation , a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today reported financial results for the three months ended September 30, 2008. “We significantly broadened our drug development pipeline through our recent acquisition of Innovive Pharmaceuticals and now have six clinical-stage candidates that address large markets. These drug assets are in varying stages of clinical development and provide us with near- and longer term potential revenue generators,” said Steven A. Kriegsman, CytRx President and CEO. “We are evaluating our clinical and non-clinical assets with a focus on advancing development of drug candidates to maximize shareh..."
05/20/2008 8-K Quarterly results
Docs: "CYTRX ANNOUNCES FIRST QUARTER 2008 FINANCIAL RESULTS LOS ANGELES — CytRx Corporation , a biopharmaceutical company engaged in the development and commercialization of therapeutics based on molecular chaperone amplification, today reported financial results for the three months ended March 31, 2008. “Late in the first quarter, RXi Pharmaceuticals Corporation initiated trading on the NASDAQ Capital Market under the ticker RXII, and we presently own 49% of RXi's outstanding common stock. Public trading of RXII provides a market valuation for this investment and increased liquidity, which has enabled us to unlock and crystallize the value of our former RNAi assets. This liquidity event was the singular watershed event for the Company during the first quarter,” said Steven A. Kriegsman, CytRx P..."
04/02/2008 8-K Quarterly results
Docs: "CYTRX REPORTS 2007 FINANCIAL RESULTS"
11/14/2007 8-K Quarterly results
Docs: "CYTRX REPORTS THIRD QUARTER 2007 FINANCIAL RESULTS"
08/10/2007 8-K Quarterly results
Docs: "CYTRX REPORTS SECOND QUARTER FINANCIAL RESULTS"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy